21Oct/13

Archway mother struck down by mystery heart failure 'turns blue' in front of … – Islington Gazette


Islington Gazette

Archway mother struck down by mystery heart failure ‘turns blue’ in front of …
Islington Gazette
Recording a verdict of death by natural causes, the coroner said: “She died of cardiac dysrhythmia – heart failure – without any real explanation as to why. “She was a healthy lady with a normal heart and nothing was identified which could cause her …

21Oct/13

Roche Holding Ltd. (ADR) (RHHBY): Roche: Impact Of Rituxan Patent Expiration … – Seeking Alpha

Roche Holding Ltd. (ADR) (RHHBY): Roche: Impact Of Rituxan Patent Expiration …
Seeking Alpha
(click to enlarge) Rituxan (rituximab), MabThera in Europe, is a monoclonal antibody against B-lymphocytes CD20 surface protein used to treat lymphomas, leukemias, transplant rejection and rheumatoid arthritis. Novartis’ Sandoz generics division is on …

21Oct/13

STENTYS to Present First Results of Sirolimus-Eluting Self-Apposing(R) Stent … – Wall Street Journal

STENTYS to Present First Results of Sirolimus-Eluting Self-Apposing(R) Stent …
Wall Street Journal
STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world’s first and only Self-Apposing(R) Stent to treat acute myocardial infarction (AMI), today announced that the 4-month results of the APPOSITION IV trial will be …

21Oct/13

STENTYS to Present First Results of Sirolimus-eluting Self-Apposing® Stent at … – 4-traders (press release)

STENTYS to Present First Results of Sirolimus-eluting Self-Apposing® Stent at …
4-traders (press release)
STENTYS (Paris:STNT) (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced that the 4-month results of the APPOSITION IV trial …

and more »